CN114107209B - Method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purpose - Google Patents
Method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purpose Download PDFInfo
- Publication number
- CN114107209B CN114107209B CN202111410684.9A CN202111410684A CN114107209B CN 114107209 B CN114107209 B CN 114107209B CN 202111410684 A CN202111410684 A CN 202111410684A CN 114107209 B CN114107209 B CN 114107209B
- Authority
- CN
- China
- Prior art keywords
- mir
- expression
- thp
- exosome
- exosomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 104
- 108091024530 miR-146a stem-loop Proteins 0.000 title claims abstract description 77
- 108091040069 miR-146a-1 stem-loop Proteins 0.000 title claims abstract description 77
- 108091081537 miR-146a-2 stem-loop Proteins 0.000 title claims abstract description 77
- 108091032392 miR-146a-3 stem-loop Proteins 0.000 title claims abstract description 77
- 230000014509 gene expression Effects 0.000 title claims abstract description 63
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 60
- 230000004069 differentiation Effects 0.000 title claims abstract description 22
- 230000010287 polarization Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title claims description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 41
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 12
- 102000004889 Interleukin-6 Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 10
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 9
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 8
- 102100025136 Macrosialin Human genes 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000012091 fetal bovine serum Substances 0.000 claims description 6
- 108091070501 miRNA Proteins 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 230000000770 proinflammatory effect Effects 0.000 claims description 6
- 238000010814 radioimmunoprecipitation assay Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000001890 transfection Methods 0.000 claims description 6
- 230000005540 biological transmission Effects 0.000 claims description 5
- 239000006143 cell culture medium Substances 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 230000003278 mimic effect Effects 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 238000010839 reverse transcription Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 108010091987 aposome Proteins 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- 238000003151 transfection method Methods 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100025222 CD63 antigen Human genes 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of biological information, in particular to a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p, which comprises the following steps: s1, preparing a high-expression miR-146a-5p exosome; s2, identifying exosomes; s3, culturing cells; s4, co-incubating exosome miR-146a-5p with THP-1 or macrophages; s5, analyzing experimental results, wherein the exosomes with high expression of miR-146a-5p, which are derived from liver cells, are prepared by a chemical transfection method, the actions of the exosomes on THP-1 differentiation and macrophage M1 polarization are explored, and genetic information substances carried by the exosomes derived from liver cells are more easily absorbed by the liver cells, wherein the exosomes obtained by the chemical transfection method have good integrity.
Description
Technical Field
The invention relates to the technical field of biological information, in particular to a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purposes.
Background
Non-alcoholic fatty liver disease (Non-alcoholic fatty liver disease, NAFLD) has become the chronic liver disease with the highest global prevalence, and studies have shown that 27% of NAFL patients progress to NASH stage, requiring drug therapeutic intervention once NASH is progressed, but no effective drug for specific treatment is currently available.
Research shows that macrophage M1 polarization can aggravate the progress of NASH, exosomes have the characteristics of high biocompatibility, escape lysosome mediated degradation, artificial modification and the like, therefore, the exosomes can be used as transport carriers of miRNAs to carry target miRNAs to specific tissues in a targeted manner to play a role in regulation, early research has proved that miR-146a-5p is a negative regulator of LPS-induced innate immunity and inflammatory response, and miR-146a-5p can inhibit release of inflammatory factors IL-1 beta, IL-6 and TNF-alpha in THP-1 cells after LPS treatment, and therefore, the invention provides a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes which express miR-146a-5p in a non-therapeutic purpose.
Disclosure of Invention
Aiming at the problems in the related art, the invention provides a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purposes, which aims to overcome the technical problems in the prior art.
In order to achieve the above purpose, the present invention provides the following technical solutions:
the invention provides a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purposes, which comprises the following steps:
s1, preparing a high-expression miR-146a-5p exosome, which specifically comprises the following steps:
(1) Respectively transfecting 50nmol/L miR-146a-5p mimic or negative control into HepG2 cells, and collecting cell culture medium supernatant after 48 hours of transfection;
(2) Obtaining an exosome with high expression of miR-146a-5p and an exosome of a control group by an ultracentrifugation method;
s2, identifying exosomes, specifically:
(1) Taking 20 μl of the extracted exosome solution, observing under a transmission electron microscope, and photographing to record the morphology of exosome;
(2) Taking 20 mu l of the extracted exosome suspension to a new EP tube of 1.5ml, adding 20 mu l of RIPA (note adding cocktail, 50:1), adding 5 XSDS (beta-mercaptoethanol) solution in a ratio of 4:1 (exosome suspension: SDS) after full cleavage, placing in a water bath of 100 ℃ for boiling for 5min, collecting a protein sample for electrophoresis, and detecting the expression of exosome marker protein CD 63;
(3) Isolating total RNA from exosomes, performing reverse transcription on the miRNA into cDNA, and quantifying the expression of miR-146a-5p by taking U6 as an internal reference;
s3, culturing cells;
s4, co-incubating exosome miR-146a-5p with THP-1 or macrophages;
s5, analyzing an experimental result.
Further, the step S3 specifically includes:
(1) HepG2 was cultured in DMEM medium supplemented with 10% fetal bovine serum, THP-1 in RPMI-1640 medium containing 10% fetal bovine serum, and both cells were cultured in a 5% CO2 incubator at 37 ℃;
(2) PMA was added to THP-1 cells in suspension culture to a final concentration of 100ng/ml to induce differentiation of THP-1 into macrophages.
Further, the step S4 specifically includes:
(1) Adding the exosomes with high expression of miR-146a-5p or exosomes of a control group into THP-1 or THP-1 differentiated macrophages (the final concentration of the exosomes is 50 mug/ml) for co-incubation for 48 hours;
(2) Taking U6 as an internal reference, quantifying the expression of THP-1 and miR-146a-5p in macrophages; quantifying the expression of MCP-1, TNF-a and IL-6 in macrophages by taking 18S as an internal reference;
(3) Cell samples were collected in 1.5mLEP tubes, after RIPA lysis was complete, 5 XSDS (beta-mercaptoethanol) was added at 4:1 to obtain protein samples, and after electrophoresis, the expression of CD68 in THP-1 cells and CD86 in macrophages was examined.
Further, the step S5 specifically includes:
(1) Compared with a control group, the expression of miR-146a-5p in HepG2 cells of the Mimic-146a-5p group and in exosomes of cell culture supernatants is obviously increased;
(2) After the aposome with high miR-146a-5p expression is incubated with THP-1 or macrophage for 48h, the expression of miR-146a-5p in the THP-1 or macrophage is obviously increased;
(3) The exosomes with high expression of miR-146a-5p can reduce the release of macrophage pro-inflammatory factors MCP-1, TNF-a and IL-6;
(4) The exosomes with high expression of miR-146a-5p can reduce the expression of a macrophage marker CD68 in THP-1 cells;
(5) The exosomes with high expression of miR-146a-5p can reduce the expression of the M1 type macrophage marker CD 86.
Compared with the prior art, the invention has the beneficial effects that:
(1) The invention relates to a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes of high-expression miR-146a-5p for non-therapeutic purposes, which is characterized in that exosomes of high-expression miR-146a-5p from liver cells are prepared by a chemical transfection method, and the exosomes of high-expression miR-146a-5p have the effect of inhibiting THP-1 differentiation and macrophage M1 polarization;
(2) The invention relates to a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes of high-expression miR-146a-5p for non-therapeutic purposes, which is characterized in that the exosomes obtained by a method of transfection and ultracentrifugation are good in integrity and high in purity;
(3) The invention relates to a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression miR-146a-5p for non-therapeutic purposes, wherein genetic information materials carried by exosomes derived from liver cells are easier to be absorbed by the liver cells;
(4) The invention relates to a method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression miR-146a-5p for non-therapeutic purposes, which is an ideal natural drug delivery carrier due to the characteristics of low immunogenicity, low toxicity, high biocompatibility, free crossing of biological barriers, escape of lysosome-mediated degradation, artificial modification and the like;
(5) The invention provides a method for inhibiting THP-1 differentiation and macrophage M1 polarization for exosomes with high expression of miR-146a-5p for non-therapeutic purposes, provides a theoretical basis for treating non-alcoholic steatohepatitis by using exosomes as a tool in the follow-up process, and provides a new direction for treating various liver diseases.
Drawings
FIG. 1 is the external body form observed by a transmission electron microscope in example 1;
FIG. 2 shows the protein level of the exosome marker CD63 of example 1;
FIG. 3 is a graph showing the expression levels of miR-146a-5p in the exosomes over-expressing miR-146a-5p in example 1 and in the exosomes of the control group;
FIG. 4 is the expression of miR-146a-5p in THP-1 cells following transfer into exosomes highly expressing miR-146a-5p in example 1;
FIG. 5 is the expression of miR-146a-5p in macrophages following the transfer of an exosome highly-expressed miR-146a-5p in example 1;
FIG. 6 is a graph showing the change in protein levels of CD68 in THP-1 cells following transfer into exosomes highly expressing miR-146a-5p in example 1;
FIG. 7 is a graph showing the change in protein levels of CD86 in macrophages following the transfection of high miR-146a-5 p-expressing exosomes in example 1;
FIG. 8 shows the expression of pro-inflammatory factors MCP-1, TNF-a, IL-6 in macrophages following the transformation of exosomes with high expression miR-146a-5p in example 1.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A method for inhibiting the polarization of THP-1 differentiated macrophage M1 by exosomes highly expressing miR-146a-5p, comprising the following steps:
s1, preparing a high-expression miR-146a-5p exosome, which specifically comprises the following steps:
(1) HepG2 cells were inoculated into 10cm cell culture dishes (inoculation density 50%), after 12h of cell growth, 50nmol/L miR-146a-5p mimic or negative control was transfected into HepG2 cells respectively using RiboFECTTMCP Reagent, and after 48h of transfection, cell culture supernatant was collected for exosome preparation;
(2) The preparation method of the cell culture medium exosome comprises the following specific preparation methods:
1) Subjecting the cell culture medium to fractional centrifugation at 300g and 2000g for 20min to eliminate large dead cells and cell debris, removing sediment after each centrifugation, and reserving the supernatant for the next centrifugation;
2) Centrifuging the obtained supernatant at 20000g for 30min to remove larger microvesicles;
3) Centrifuging the obtained supernatant at 100,000g for 70min to collect exosome precipitate, washing the exosome precipitate with 6ml PBS once, centrifuging at 100,000g for 70min to obtain exosome with high expression of miR-146a-5p and exosome of control group;
s2, identifying exosomes, specifically:
(1) Transmission electron microscope: placing 20 μl of the extracted exosome solution on a copper grid, carrying out negative dyeing for 5min with 3% phosphotungstic acid aqueous solution, drying the grid under an incandescent lamp for 10min, placing under a transmission electron microscope for observation, and photographing to record the morphology of the exosome;
(2) Exosome marker protein detection: separately taking 20 μl of the extracted exosome suspension to a new EP tube of 1.5ml, adding 20 μl RIPA (note adding cocktail, 50:1), lysing for 30min at 4deg.C, not centrifuging, taking 2.5 μl of BCA, adding 5SDS (beta-mercaptoethanol) solution to the rest sample at a ratio of 4:1 (exosome suspension: SDS), boiling in 100deg.C water bath for 5min, electrophoresis using 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE), transferring proteins to polyvinylidene fluoride (PVDF) membrane after electrophoresis, blocking membrane with 5% BSA at room temperature for 1h, then incubating overnight at 4deg.C with primary antibody CD63 (Santacruzsc-5275), and detecting protein expression of CD 63;
(3) And (3) detecting the expression quantity of miR-146a-5p in the exosome: total RNA was isolated from exosomes with Trizol (RNAexProReagent, AG), and miRNA was reverse transcribed to cDNA using the mircutePlusmiRNA first strand cDNA kit (TIANGEN, KR 211), and miR-146a-5p expression was quantified using the mircutePlusmiRNAqPCRKit (TIANGEN, FP 411) kit, with U6 as an internal reference;
s3, culturing cells;
s4, co-incubating exosome miR-146a-5p with THP-1 or macrophages;
s5, analyzing an experimental result.
The step S3 specifically includes:
(1) Purchasing a human liver cancer cell line HepG2 and a monocyte cell line THP-1, culturing the HepG2 in a DMEM medium added with 10% fetal bovine serum, culturing the THP-1 in an RPMI-1640 medium containing 10% fetal bovine serum, and culturing both cells in a 5% CO2 incubator at 37 ℃;
(2) THP-1 differentiation: PMA was added to THP-1 cells cultured in suspension to a final concentration of 100ng/ml to induce differentiation of THP-1 into macrophages, after 48 hours of induction, the medium was removed, and the cells were washed 2 times with PBS, and differentiation of THP-1 cells was observed under a microscope to obtain fully differentiated macrophages.
The step S4 specifically includes:
(1) Exosomes miR-146a-5p co-incubate with THP-1 or macrophages: adding the exosomes with high expression of miR-146a-5p or exosomes of a control group into THP-1 or THP-1 differentiated macrophages (the final concentration of the exosomes is 50 mug/ml) for co-incubation for 48 hours;
(2) Detection of the expression levels of miR-146a-5p in THP-1 cells and miR-146a-5p in macrophages, MCP-1, TNF-a and IL-6: collecting cells, isolating total RNA from the cells with Trizol (RNAexProReagent, AG), reverse-transcribing miRNA into cDNA using a miRcutePlusmiRNA first strand cDNA kit (TIANGEN, KR 211), and quantifying miR-146a-5p expression using a miRcutePlusmiRNAqPCRK (TIANGEN, FP 411) kit with U6 as an internal reference; reverse transcription of mRNA into cDNA using PrimeScript TMRT kit, quantification of MCP-1, TNF-a, IL-6 expression using SYBRGreenPCR kit, 18S as reference;
the QPCR primer sequences were:
(3) Detection of macrophage marker protein CD68 in THP-1 cells and M1 type macrophage marker protein CD86 in macrophages: cell samples were collected in 1.5mLEP tubes, washed 2 times with PBS, added with 100ul RIPA (containing 1. Mu. Protease inhibitor and 1. Mu. Phosphatase inhibitor), blown to complete digestion of the cells with a gun, after Votext shaking, the tubes were placed in a 4 degree decolorizing shaker for full lysis 30min, after Votext shaking, centrifuged at 12000RPM for 30min with a 4 degree centrifuge, the supernatant was extracted, added with 5 XSDS (containing beta-mercaptoethanol) at 4:1, then metal cooked at 100℃for 3-5min, and each sample was electrophoresed with 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). After electrophoresis, the proteins were transferred to polyvinylidene fluoride (PVDF) membrane, the membrane was blocked with 5% BSA for 1h at room temperature, and then incubated with primary antibody CD86 (Santacruzsc-28347) overnight at 4℃to examine the protein expression of CD68 and CD 86.
The step S5 specifically comprises the following steps:
(1) Compared with a control group, the expression of miR-146a-5p in the exosomes of the cell culture supernatant of the Mimic-146a-5p group is obviously increased;
(2) After the exosomes with high miR-146a-5p expression are incubated with the macrophages for 48 hours, the miR-146a-5p expression in the macrophages is obviously increased;
(3) The exosomes with high expression of miR-146a-5p can reduce the release of pro-inflammatory factors MCP-1, TNF-a and IL-6.
(4) The exosomes with high miR-146a-5p expression can reduce the expression of macrophage marker CD68 in THP-1 cells
(5) The exosomes with high expression of miR-146a-5p can reduce the expression of the M1 type macrophage marker CD 86.
The invention prepares the exosome of the over-expression miR-146a-5p, and incubates the exosome with THP-1 or macrophage, and experimental results prove that the exosome miR-146a-5p can inhibit THP-1 differentiation and macrophage M1 polarization, and can reduce release of macrophage pro-inflammatory factors MCP-1, TNF-alpha and IL-6.
In order to ensure the structural integrity of exosome membranes, the exosome with high expression of miR-146a-5p from liver cells is prepared by a method of transfection and ultracentrifugation, and the invention proves that the exosome from liver cells is taken as a carrier to carry miR-146a-5p, so that THP-1 differentiation and macrophage M1 polarization can be inhibited, and the release of pro-inflammatory factors is reduced. The research provides theoretical basis for the subsequent treatment of nonalcoholic steatohepatitis by using exosomes as tools, and simultaneously provides a new direction for the treatment of various liver diseases.
The above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (2)
1. A method for inhibiting THP-1 differentiation and macrophage M1 polarization in a non-therapeutic, high miR-146a-5 p-expressing exosome comprising the steps of:
s1, preparing a high-expression miR-146a-5p exosome, which specifically comprises the following steps:
(1) Inoculating HepG2 cells into a 10cm cell culture dish, after growing the cells for 12 hours, respectively transfecting 50nmol/L miR-146a-5p mimic or negative control into the HepG2 cells by using RiboFECTTMCP Reagent, and collecting cell culture medium supernatant after 48 hours of transfection for exogenesis;
(2) Subjecting the cell culture medium to fractional centrifugation at 300g and 2000g for 20min to eliminate large dead cells and cell debris, removing sediment after each centrifugation, and reserving the supernatant for the next centrifugation; centrifuging the obtained supernatant at 20000g for 30min to remove larger microvesicles; centrifuging the obtained supernatant at 100,000g for 70min to collect exosome precipitate, washing the exosome precipitate with 6ml PBS for one time, and centrifuging at 100,000g for 70min to obtain exosome with high expression of miR-146a-5p and exosome of control group;
s2, identifying exosomes, specifically:
(1) Taking 20 μl of the extracted exosome solution, observing under a transmission electron microscope, and photographing to record the morphology of exosome;
(2) Taking 20 mu l of the extracted exosome suspension to a new EP tube of 1.5ml, adding 20 mu l of RIPA, adding 5 XSDS solution according to a ratio of 4:1 after full cleavage, placing in a water bath of 100 ℃ for boiling for 5min, collecting a protein sample for electrophoresis, and detecting the expression condition of exosome marker protein CD 63;
(3) Isolating total RNA from exosomes, performing reverse transcription on the miRNA into cDNA, and quantifying the expression of miR-146a-5p by taking U6 as an internal reference;
s3, culturing cells: hepG2 was cultured in DMEM medium supplemented with 10% fetal bovine serum, THP-1 in RPMI-1640 medium containing 10% fetal bovine serum, and both cells were cultured in a 5% CO2 incubator at 37 ℃; PMA was then added to suspension-cultured THP-1 cells to a final concentration of 100ng/ml to induce differentiation of THP-1 into macrophages;
s4, co-incubation of exosome miR-146a-5p with THP-1 or macrophages: adding an exosome with high miR-146a-5p expression or a control exosome into THP-1 or THP-1 differentiated macrophages for co-incubation for 48h; taking U6 as an internal reference, quantifying the expression of THP-1 and miR-146a-5p in macrophages; quantifying the expression of MCP-1, TNF-a and IL-6 in macrophages by taking 18S as an internal reference; collecting cell samples in a 1.5mLEP tube, adding 5 xSDS at a ratio of 4:1 after RIPA is fully cracked to obtain protein samples, and detecting the expression of CD68 in THP-1 cells and CD86 in macrophages after electrophoresis;
s5, analyzing an experimental result.
2. The method of claim 1, wherein step S5 comprises the steps of:
(1) Compared with a control group, the expression of miR-146a-5p in HepG2 cells of the Mimic-146a-5p group and in exosomes of cell culture supernatants is obviously increased;
(2) After the aposome with high miR-146a-5p expression is incubated with THP-1 or macrophage for 48h, the expression of miR-146a-5p in the THP-1 or macrophage is obviously increased;
(3) The exosomes with high expression of miR-146a-5p can reduce the release of macrophage pro-inflammatory factors MCP-1, TNF-a and IL-6;
(4) The exosomes with high expression of miR-146a-5p can reduce the expression of a macrophage marker CD68 in THP-1 cells;
(5) The exosomes with high expression of miR-146a-5p can reduce the expression of the M1 type macrophage marker CD 86.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111410684.9A CN114107209B (en) | 2021-11-25 | 2021-11-25 | Method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purpose |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111410684.9A CN114107209B (en) | 2021-11-25 | 2021-11-25 | Method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purpose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114107209A CN114107209A (en) | 2022-03-01 |
| CN114107209B true CN114107209B (en) | 2024-02-02 |
Family
ID=80375494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111410684.9A Active CN114107209B (en) | 2021-11-25 | 2021-11-25 | Method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purpose |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114107209B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475645A (en) * | 2016-04-29 | 2019-03-15 | 先进瑞金医疗技术有限公司 | MicroRNA composition and its preparation and application |
| CN111534491A (en) * | 2020-05-09 | 2020-08-14 | 胡宗强 | Experimental method for inhibiting growth of liver cancer cells by miR-9 inhibitor |
| CN112210534A (en) * | 2020-09-03 | 2021-01-12 | 遵义医科大学附属医院 | Method for efficiently inducing macrophage in vitro polarization by sequential method |
| CN112442534A (en) * | 2020-11-06 | 2021-03-05 | 温州医科大学 | Application of circulating blood exosome miR-146a-5p as retinal vein occlusion treatment and prognosis evaluation marker |
| CN113082216A (en) * | 2021-04-25 | 2021-07-09 | 吉林大学 | Glioma cell exosome containing miR-124 and preparation method and application thereof |
-
2021
- 2021-11-25 CN CN202111410684.9A patent/CN114107209B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475645A (en) * | 2016-04-29 | 2019-03-15 | 先进瑞金医疗技术有限公司 | MicroRNA composition and its preparation and application |
| CN111534491A (en) * | 2020-05-09 | 2020-08-14 | 胡宗强 | Experimental method for inhibiting growth of liver cancer cells by miR-9 inhibitor |
| CN112210534A (en) * | 2020-09-03 | 2021-01-12 | 遵义医科大学附属医院 | Method for efficiently inducing macrophage in vitro polarization by sequential method |
| CN112442534A (en) * | 2020-11-06 | 2021-03-05 | 温州医科大学 | Application of circulating blood exosome miR-146a-5p as retinal vein occlusion treatment and prognosis evaluation marker |
| CN113082216A (en) * | 2021-04-25 | 2021-07-09 | 吉林大学 | Glioma cell exosome containing miR-124 and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment;Pei-pei Hou 等;Molecular Cell;第78卷;1192-1206、e1-e10 * |
| Exosomes Derived from MicroRNA-146a-5p-Enriched Bone Marrow Mesenchymal Stem Cells Alleviate Intracerebral Hemorrhage by Inhibiting Neuronal Apoptosis and Microglial M1 Polarization;Shurong Duan 等;Drug Design, Development and Therapy;第14卷;3143-3158 * |
| Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192-5p Activates Macrophages Through Rictor/Akt/ Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease;Xiao-Lin Liu 等;Hepatology;1-16及SI * |
| 肺腺癌细胞源性外泌体活化的人THP-1巨噬细胞促进肺癌细胞的侵袭;陈良远 等;细胞与分子免疫学杂志;第35卷(第11期);967-972 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114107209A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111154763B (en) | Application of long-chain non-coding RNA lncMGPF in regulation and control of pig muscle development function | |
| CN114404441B (en) | Promoter for bone marrow mesenchymal stem cell osteogenic differentiation | |
| CN108179194B (en) | Tumor molecular marker circBIRC6, and inhibitor and application thereof | |
| CN110384800B (en) | Application of LncRNA XLOC _075168 in preparation of medicine for promoting angiogenesis | |
| CN108315440B (en) | MiRNA marker for distinguishing buffalo milk from cow milk and application thereof | |
| CN112852818A (en) | Circular RNA hsa _ circ _0001550 and application thereof | |
| CN108913695B (en) | Application of ZEB1 in human heart fibroblast | |
| CN114107209B (en) | Method for inhibiting THP-1 differentiation and macrophage M1 polarization by exosomes with high expression of miR-146a-5p for non-therapeutic purpose | |
| CN110846315B (en) | Long-chain non-coding RNA XLOC _102237 and application thereof in human umbilical vein endothelial cells | |
| CN112410439B (en) | Application of chi-miR-128-3p as goat follicle maturation miRNA marker | |
| CN112481218A (en) | Cell line for knocking out pig miR-155 gene based on CRISPR/Cas9 gene editing system and construction method | |
| CN114958849B (en) | Application of lncRNACACF to miR-520b-3p adsorption in regulation of human umbilical vein endothelial cell cycle | |
| CN109337926B (en) | Method for constructing haplotype chicken myoblasts with high let-7b mature body expression | |
| CN113637641B (en) | Application of DAPK variable shear transcript in osteoblast differentiation of mesenchymal stem cells | |
| CN114702566B (en) | Small peptide encoded by long-chain non-coding RNA LINC01234 and application thereof | |
| CN116426648B (en) | miRNA combination for identifying stem cell exosomes and qRCR primer thereof | |
| CN112662621B (en) | Method for reversing mesenchymal stem cell aging and application | |
| CN111549033B (en) | Lentiviral-infected human epidermal keratinocyte strain and construction method and application thereof | |
| CN113350368B (en) | Application of gene inhibitor in preparation of epidermal stem cell migration pharmaceutical preparation | |
| CN114292875B (en) | Bovine CFL2 gene adenovirus interference vector and construction and identification method thereof | |
| CN115961025A (en) | Application of circular RNA in preparation of products related to myocardial hypertrophy | |
| CN112251465A (en) | Application of TZAP gene or protein as target spot for improving mesenchymal stem cell proliferation and differentiation capacity | |
| CN117987526A (en) | Application of NF2 gene in repairing and regenerating defective skull | |
| CN112843083A (en) | Acute myocardial infarction treatment medicine | |
| CN113025637A (en) | Bacterial origin anti-tumor PNPase gene and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |